Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen 4/B7 (CTLA-4/B7) pathways are key regulators in T-cell activation and tolerance. Nivolumab, pembrolizumab (PD-1 inhibitors), atezolizumab (PD-L1 inhibitor) and ipilimumab (CTLA-4 in...
Main Authors: | Isabella Lupi, Alessandro Brancatella, Mirco Cosottini, Nicola Viola, Giulia Lanzolla, Daniele Sgrò, Giulia Di Dalmazi, Francesco Latrofa, Patrizio Caturegli, Claudio Marcocci |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2019-10-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Online Access: | https://doi.org/10.1530/EDM-19-0102 |
Similar Items
-
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
by: Elizabeth Ahern, et al.
Published: (2018-06-01) -
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01) -
Drug response to PD-1/PD-L1 blockade: based on biomarkers
by: Chen Q, et al.
Published: (2018-08-01) -
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
by: Chen CY, et al.
Published: (2018-07-01) -
PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
by: Li, Vivian
Published: (2021)